DUBLIN – Maat Pharma SA returns to the American Society of Hematology (ASH) annual meeting next month with a complete readout of its phase Ib/IIa trial of autologous fecal microbiota transfer (FMT) to combat dysbiosis in acute myeloid leukemia (AML) patients undergoing intensive induction chemotherapy. The company posted interim data from the same study last year.